Press release

09/04/2020

Nanobiotix announces half-year financial statements as at June 30, 2020

• Download en

08/03/2020

Update to the Nanobiotix press release dated july 28, 2020

• Download en

Update to the Nanobiotix press release dated july 28, 2020

The following pages contain information regarding the [potential] capital increase of Nanobiotix. For regulatory reasons, the distribution of the content of such information is restricted. Consequently, please fill out the fields below to access such information.

Your country: Select your country Andorra United Arab Emirates Afghanistan Antigua and Barbuda Anguilla Albania Armenia Angola Antarctica Argentina American Samoa Austria Australia Aruba Aland Islands Azerbaijan Bosnia and Herzegovina Barbados Bangladesh Belgium Burkina Faso Bulgaria Bahrain Burundi Benin Saint Barthelemy Bermuda Brunei Bolivia Bonaire, Saint Eustatius and Saba Brazil Bahamas Bhutan Bouvet Island Botswana Belarus Belize Canada Cocos Islands Democratic Republic of the Congo Central African Republic Republic of the Congo Switzerland Ivory Coast Cook Islands Chile Cameroon China Colombia Costa Rica Cuba Cape Verde Curacao Christmas Island Cyprus Czech Republic Germany Djibouti Denmark Dominica Dominican Republic Algeria Ecuador Estonia Egypt Western Sahara Eritrea Spain Ethiopia Finland Fiji Falkland Islands Micronesia Faroe Islands France Gabon United Kingdom Grenada Georgia French Guiana Guernsey Ghana Gibraltar Greenland Gambia Guinea Guadeloupe Equatorial Guinea Greece South Georgia and the South Sandwich Islands Guatemala Guam Guinea-Bissau Guyana Hong Kong Heard Island and McDonald Islands Honduras Croatia Haiti Hungary Indonesia Ireland Israel Isle of Man India British Indian Ocean Territory Iraq Iran Iceland Italy Jersey Jamaica Jordan Japan Kenya Kyrgyzstan Cambodia Kiribati Comoros Saint Kitts and Nevis North Korea South Korea Kuwait Cayman Islands Kazakhstan Laos Lebanon Saint Lucia Liechtenstein Sri Lanka Liberia Lesotho Lithuania Luxembourg Latvia Libya Morocco Monaco Moldova Montenegro Saint Martin Madagascar Marshall Islands Macedonia Mali Myanmar Mongolia Macao Northern Mariana Islands Martinique Mauritania Montserrat Malta Mauritius Maldives Malawi Mexico Malaysia Mozambique Namibia New Caledonia Niger Norfolk Island Nigeria Nicaragua Netherlands Norway Nepal Nauru Niue New Zealand Oman Panama Peru French Polynesia Papua New Guinea Philippines Pakistan Poland Saint Pierre and Miquelon Pitcairn Puerto Rico Palestinian Territory Portugal Palau Paraguay Qatar Reunion Romania Serbia Russia Rwanda Saudi Arabia Solomon Islands Seychelles Sudan Sweden Singapore Saint Helena Slovenia Svalbard and Jan Mayen Slovakia Sierra Leone San Marino Senegal Somalia Suriname South Sudan Sao Tome and Principe El Salvador Sint Maarten Syria Swaziland Turks and Caicos Islands Chad French Southern Territories Togo Thailand Tajikistan Tokelau East Timor Turkmenistan Tunisia Tonga Turkey Trinidad and Tobago Tuvalu Taiwan Tanzania Ukraine Uganda United States Minor Outlying Islands United States Uruguay Uzbekistan Vatican Saint Vincent and the Grenadines Venezuela British Virgin Islands U.S. Virgin Islands Vietnam Vanuatu Wallis and Futuna Samoa Kosovo Yemen Mayotte South Africa Zambia Zimbabwe

Access to this information is restricted to persons who are located outside the United States, Canada, Japan and Australia.

The following pages include information pertaining to a potential capital increase of Nanobiotix, which would be conducted pursuant to a public offering in France exclusively, if it is conducted in the future at all. This website and the information contained herein are not intended for, and may not be accessed by, or distributed or disseminated to, persons resident or physically present in the United States of America (including its territories, the “United States”), Canada, Japan or Australia, and do not constitute an offer to sell or the solicitation of an offer to purchase or acquire, any shares or other securities of Nanobiotix in the United States, Canada, Japan or Australia. The shares of Nanobiotix referred to on this website have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), and may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act. All persons residing outside of France and outside of the United States, Canada, Japan and Australia who wish to access the documents contained on this website should first ensure that they are not subject to local laws or regulations that prohibit or restrict their right to access this website, or require registration or approval for any acquisition of securities by them. No such registration or approval has been or will be obtained outside of France. Nanobiotix assumes no responsibility if there is a violation of applicable law and regulations by any person. I certify that: I am a resident of and physically present in France; Or (2) I am a resident of and physically present in a Member State of the European Economic Area (other than France) or the United Kingdom which is subject to the provisions of Regulation (EU) 2017/1129 of the European Parliament of the Council of June 14, 2017 (the “Prospectus Regulation”), and I am a qualified investor as defined in the Prospectus Regulation, And (3) I am not a resident of or physically present in the United States, Canada, Japan or Australia. I have read and understood the foregoing, and hereby make the certifications above and agree to comply with all of the above restrictions:

Agree & download

Sorry

Not for access within the United States, Canada, Japan or Australia

07/28/2020

Nanobiotix successfully raises approximatively €20 million in placement of ordinary new shares with US and european investors

• Download en

Nanobiotix successfully raises approximatively €20 million in placement of ordinary new shares with US and european investors

The following pages contain information regarding the [potential] capital increase of Nanobiotix. For regulatory reasons, the distribution of the content of such information is restricted. Consequently, please fill out the fields below to access such information.

Your country: Select your country Andorra United Arab Emirates Afghanistan Antigua and Barbuda Anguilla Albania Armenia Angola Antarctica Argentina American Samoa Austria Australia Aruba Aland Islands Azerbaijan Bosnia and Herzegovina Barbados Bangladesh Belgium Burkina Faso Bulgaria Bahrain Burundi Benin Saint Barthelemy Bermuda Brunei Bolivia Bonaire, Saint Eustatius and Saba Brazil Bahamas Bhutan Bouvet Island Botswana Belarus Belize Canada Cocos Islands Democratic Republic of the Congo Central African Republic Republic of the Congo Switzerland Ivory Coast Cook Islands Chile Cameroon China Colombia Costa Rica Cuba Cape Verde Curacao Christmas Island Cyprus Czech Republic Germany Djibouti Denmark Dominica Dominican Republic Algeria Ecuador Estonia Egypt Western Sahara Eritrea Spain Ethiopia Finland Fiji Falkland Islands Micronesia Faroe Islands France Gabon United Kingdom Grenada Georgia French Guiana Guernsey Ghana Gibraltar Greenland Gambia Guinea Guadeloupe Equatorial Guinea Greece South Georgia and the South Sandwich Islands Guatemala Guam Guinea-Bissau Guyana Hong Kong Heard Island and McDonald Islands Honduras Croatia Haiti Hungary Indonesia Ireland Israel Isle of Man India British Indian Ocean Territory Iraq Iran Iceland Italy Jersey Jamaica Jordan Japan Kenya Kyrgyzstan Cambodia Kiribati Comoros Saint Kitts and Nevis North Korea South Korea Kuwait Cayman Islands Kazakhstan Laos Lebanon Saint Lucia Liechtenstein Sri Lanka Liberia Lesotho Lithuania Luxembourg Latvia Libya Morocco Monaco Moldova Montenegro Saint Martin Madagascar Marshall Islands Macedonia Mali Myanmar Mongolia Macao Northern Mariana Islands Martinique Mauritania Montserrat Malta Mauritius Maldives Malawi Mexico Malaysia Mozambique Namibia New Caledonia Niger Norfolk Island Nigeria Nicaragua Netherlands Norway Nepal Nauru Niue New Zealand Oman Panama Peru French Polynesia Papua New Guinea Philippines Pakistan Poland Saint Pierre and Miquelon Pitcairn Puerto Rico Palestinian Territory Portugal Palau Paraguay Qatar Reunion Romania Serbia Russia Rwanda Saudi Arabia Solomon Islands Seychelles Sudan Sweden Singapore Saint Helena Slovenia Svalbard and Jan Mayen Slovakia Sierra Leone San Marino Senegal Somalia Suriname South Sudan Sao Tome and Principe El Salvador Sint Maarten Syria Swaziland Turks and Caicos Islands Chad French Southern Territories Togo Thailand Tajikistan Tokelau East Timor Turkmenistan Tunisia Tonga Turkey Trinidad and Tobago Tuvalu Taiwan Tanzania Ukraine Uganda United States Minor Outlying Islands United States Uruguay Uzbekistan Vatican Saint Vincent and the Grenadines Venezuela British Virgin Islands U.S. Virgin Islands Vietnam Vanuatu Wallis and Futuna Samoa Kosovo Yemen Mayotte South Africa Zambia Zimbabwe

Access to this information is restricted to persons who are located outside the United States, Canada, Japan and Australia.

The following pages include information pertaining to a potential capital increase of Nanobiotix, which would be conducted pursuant to a public offering in France exclusively, if it is conducted in the future at all. This website and the information contained herein are not intended for, and may not be accessed by, or distributed or disseminated to, persons resident or physically present in the United States of America (including its territories, the “United States”), Canada, Japan or Australia, and do not constitute an offer to sell or the solicitation of an offer to purchase or acquire, any shares or other securities of Nanobiotix in the United States, Canada, Japan or Australia. The shares of Nanobiotix referred to on this website have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), and may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act. All persons residing outside of France and outside of the United States, Canada, Japan and Australia who wish to access the documents contained on this website should first ensure that they are not subject to local laws or regulations that prohibit or restrict their right to access this website, or require registration or approval for any acquisition of securities by them. No such registration or approval has been or will be obtained outside of France. Nanobiotix assumes no responsibility if there is a violation of applicable law and regulations by any person. I certify that: I am a resident of and physically present in France; Or (2) I am a resident of and physically present in a Member State of the European Economic Area (other than France) or the United Kingdom which is subject to the provisions of Regulation (EU) 2017/1129 of the European Parliament of the Council of June 14, 2017 (the “Prospectus Regulation”), and I am a qualified investor as defined in the Prospectus Regulation, And (3) I am not a resident of or physically present in the United States, Canada, Japan or Australia. I have read and understood the foregoing, and hereby make the certifications above and agree to comply with all of the above restrictions:

Agree & download

Sorry

Not for access within the United States, Canada, Japan or Australia

07/27/2020

Nanobiotix launches a placement

• Download en

Title

The following pages contain information regarding the [potential] capital increase of Nanobiotix. For regulatory reasons, the distribution of the content of such information is restricted. Consequently, please fill out the fields below to access such information.

Your country: Select your country Andorra United Arab Emirates Afghanistan Antigua and Barbuda Anguilla Albania Armenia Angola Antarctica Argentina American Samoa Austria Australia Aruba Aland Islands Azerbaijan Bosnia and Herzegovina Barbados Bangladesh Belgium Burkina Faso Bulgaria Bahrain Burundi Benin Saint Barthelemy Bermuda Brunei Bolivia Bonaire, Saint Eustatius and Saba Brazil Bahamas Bhutan Bouvet Island Botswana Belarus Belize Canada Cocos Islands Democratic Republic of the Congo Central African Republic Republic of the Congo Switzerland Ivory Coast Cook Islands Chile Cameroon China Colombia Costa Rica Cuba Cape Verde Curacao Christmas Island Cyprus Czech Republic Germany Djibouti Denmark Dominica Dominican Republic Algeria Ecuador Estonia Egypt Western Sahara Eritrea Spain Ethiopia Finland Fiji Falkland Islands Micronesia Faroe Islands France Gabon United Kingdom Grenada Georgia French Guiana Guernsey Ghana Gibraltar Greenland Gambia Guinea Guadeloupe Equatorial Guinea Greece South Georgia and the South Sandwich Islands Guatemala Guam Guinea-Bissau Guyana Hong Kong Heard Island and McDonald Islands Honduras Croatia Haiti Hungary Indonesia Ireland Israel Isle of Man India British Indian Ocean Territory Iraq Iran Iceland Italy Jersey Jamaica Jordan Japan Kenya Kyrgyzstan Cambodia Kiribati Comoros Saint Kitts and Nevis North Korea South Korea Kuwait Cayman Islands Kazakhstan Laos Lebanon Saint Lucia Liechtenstein Sri Lanka Liberia Lesotho Lithuania Luxembourg Latvia Libya Morocco Monaco Moldova Montenegro Saint Martin Madagascar Marshall Islands Macedonia Mali Myanmar Mongolia Macao Northern Mariana Islands Martinique Mauritania Montserrat Malta Mauritius Maldives Malawi Mexico Malaysia Mozambique Namibia New Caledonia Niger Norfolk Island Nigeria Nicaragua Netherlands Norway Nepal Nauru Niue New Zealand Oman Panama Peru French Polynesia Papua New Guinea Philippines Pakistan Poland Saint Pierre and Miquelon Pitcairn Puerto Rico Palestinian Territory Portugal Palau Paraguay Qatar Reunion Romania Serbia Russia Rwanda Saudi Arabia Solomon Islands Seychelles Sudan Sweden Singapore Saint Helena Slovenia Svalbard and Jan Mayen Slovakia Sierra Leone San Marino Senegal Somalia Suriname South Sudan Sao Tome and Principe El Salvador Sint Maarten Syria Swaziland Turks and Caicos Islands Chad French Southern Territories Togo Thailand Tajikistan Tokelau East Timor Turkmenistan Tunisia Tonga Turkey Trinidad and Tobago Tuvalu Taiwan Tanzania Ukraine Uganda United States Minor Outlying Islands United States Uruguay Uzbekistan Vatican Saint Vincent and the Grenadines Venezuela British Virgin Islands U.S. Virgin Islands Vietnam Vanuatu Wallis and Futuna Samoa Kosovo Yemen Mayotte South Africa Zambia Zimbabwe

Access to this information is restricted to persons who are located outside the United States, Canada, Japan and Australia.

The following pages include information pertaining to a potential capital increase of Nanobiotix, which would be conducted pursuant to a public offering in France exclusively, if it is conducted in the future at all. This website and the information contained herein are not intended for, and may not be accessed by, or distributed or disseminated to, persons resident or physically present in the United States of America (including its territories, the “United States”), Canada, Japan or Australia, and do not constitute an offer to sell or the solicitation of an offer to purchase or acquire, any shares or other securities of Nanobiotix in the United States, Canada, Japan or Australia. The shares of Nanobiotix referred to on this website have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), and may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act. All persons residing outside of France and outside of the United States, Canada, Japan and Australia who wish to access the documents contained on this website should first ensure that they are not subject to local laws or regulations that prohibit or restrict their right to access this website, or require registration or approval for any acquisition of securities by them. No such registration or approval has been or will be obtained outside of France. Nanobiotix assumes no responsibility if there is a violation of applicable law and regulations by any person. I certify that: I am a resident of and physically present in France; Or (2) I am a resident of and physically present in a Member State of the European Economic Area (other than France) or the United Kingdom which is subject to the provisions of Regulation (EU) 2017/1129 of the European Parliament of the Council of June 14, 2017 (the “Prospectus Regulation”), and I am a qualified investor as defined in the Prospectus Regulation, And (3) I am not a resident of or physically present in the United States, Canada, Japan or Australia. I have read and understood the foregoing, and hereby make the certifications above and agree to comply with all of the above restrictions:”

Agree & download

Sorry

Not for access within the United States, Canada, Japan or Australia

07/17/2020

Nanobiotix announces revenue for second quarter 2020 and first half year 2020

• Download en

06/17/2020

Nanobiotix receives feedback from US FDA to advance phase III head and neck cancer study design and CMC development plan for NDA

• Download en

06/10/2020

Nanobiotix spinoff Curadigm validates novel nanoprimer technology in RNA therapeutics

• Download en

06/08/2020

Nanobiotix secures €10M in non-dilutive financing

• Download fr
• Download en

05/29/2020

Nanobiotix announces positive first results from phase I expansion in locally advanced head and neck cancer at ASCO 2020

• Download en

05/14/2020

Publication of the 2019 Universal Registration Document

• Download en

05/06/2020

Nanobiotix announces first phase I trial with NBTXR3 in pancreatic cancer is safe to proceed per US FDA

• Download en

04/30/2020

Nanobiotix announces first quarter 2020 revenues

• Download en

04/21/2020

Nanobiotix provides updates on clinical development continuity in the context of the Covid-19 crisis

• Download en

03/17/2020

Nanobiotix 2019 Annual results

• Download en

02/28/2020

Nanobiotix 2019 Q4 and annual revenues

• Download en

02/10/2020

Scientific Clinical | Nanobiotix announces Fast Track designation granted by U.S. FDA for investigation of first-in-class NBTXR3 in Head and Neck cancer

• Download en

01/07/2020

Scientific Clinical | Nanobiotix announces plan for global phase III Head and Neck cancer registration trial along with overall development update

• Download en

07/27/2020

Nanobiotix raises approximately EUR 29.5 million in placement of ordinary new shares

• Download en

12/16/2019

Corporate | Nanobiotix receives the 2019 Prix Galien award for first-in-class Hensify

• Download en

11/12/2019

Scientific Clinical | Nanobiotix announces new results from pre-clinical immuno-oncology study at SITC 2019

• Download en

10/25/2019

Financial | Nanobiotix announces third quarter 2019 revenue

• Download en

09/18/2019

Scientific Clinical | Phase I study results show first-in-class NBTXR3 could present as a valuable option for patients with hepatocellular carcinoma or liver metastasis

• Download en

09/11/2019

Financial | Nanobiotix announces half year financial statements of june 30, 2019

• Download en

09/11/2019

Financial | Nanobiotix announces second quarter 2019 revenue

• Download en

09/11/2019

Scientific Clinical | Nanobiotix announces publication of phase III soft tissue sarcoma data for first-in-class NBTXR3 in the Lancet Oncology

• Download en

09/11/2019

Corporate | Nanobiotix announces new organizational structure as the company enters its next stage after first european market approval

• Download en

08/08/2019

Nanobiotix launches a placement

• Download en

06/04/2019

Corporate | Nanobiotix appoints new chief medical officer as the company evolves after achievement of european market approval

• Download en

05/28/2019

Scientific Clinical | Nanobiotix announces the launch of Curadigm : A new nanotechnology platform for healthcare

• Download en

04/30/2019

Financial | Nanobiotix announces first quarter 2019 revenue

• Download en

04/25/2019

Financial | Laurent Levy, CEO, increases stake in Nanobiotix's capital

• Download en

04/09/2019

Nanobiotix raises approximately EUR 29.5 million in placement of ordinary new shares

• Download en

Nanobiotix raises approximately EUR 29.5 million in placement of ordinary new shares

The following pages contain information regarding the placement of Nanobiotix. For regulatory reasons, the distribution of the content of such information is restricted. Consequently, please fill out the fields below to access such information.

Your country: Select your country Andorra United Arab Emirates Afghanistan Antigua and Barbuda Anguilla Albania Armenia Angola Antarctica Argentina American Samoa Austria Australia Aruba Aland Islands Azerbaijan Bosnia and Herzegovina Barbados Bangladesh Belgium Burkina Faso Bulgaria Bahrain Burundi Benin Saint Barthelemy Bermuda Brunei Bolivia Bonaire, Saint Eustatius and Saba Brazil Bahamas Bhutan Bouvet Island Botswana Belarus Belize Canada Cocos Islands Democratic Republic of the Congo Central African Republic Republic of the Congo Switzerland Ivory Coast Cook Islands Chile Cameroon China Colombia Costa Rica Cuba Cape Verde Curacao Christmas Island Cyprus Czech Republic Germany Djibouti Denmark Dominica Dominican Republic Algeria Ecuador Estonia Egypt Western Sahara Eritrea Spain Ethiopia Finland Fiji Falkland Islands Micronesia Faroe Islands France Gabon United Kingdom Grenada Georgia French Guiana Guernsey Ghana Gibraltar Greenland Gambia Guinea Guadeloupe Equatorial Guinea Greece South Georgia and the South Sandwich Islands Guatemala Guam Guinea-Bissau Guyana Hong Kong Heard Island and McDonald Islands Honduras Croatia Haiti Hungary Indonesia Ireland Israel Isle of Man India British Indian Ocean Territory Iraq Iran Iceland Italy Jersey Jamaica Jordan Japan Kenya Kyrgyzstan Cambodia Kiribati Comoros Saint Kitts and Nevis North Korea South Korea Kuwait Cayman Islands Kazakhstan Laos Lebanon Saint Lucia Liechtenstein Sri Lanka Liberia Lesotho Lithuania Luxembourg Latvia Libya Morocco Monaco Moldova Montenegro Saint Martin Madagascar Marshall Islands Macedonia Mali Myanmar Mongolia Macao Northern Mariana Islands Martinique Mauritania Montserrat Malta Mauritius Maldives Malawi Mexico Malaysia Mozambique Namibia New Caledonia Niger Norfolk Island Nigeria Nicaragua Netherlands Norway Nepal Nauru Niue New Zealand Oman Panama Peru French Polynesia Papua New Guinea Philippines Pakistan Poland Saint Pierre and Miquelon Pitcairn Puerto Rico Palestinian Territory Portugal Palau Paraguay Qatar Reunion Romania Serbia Russia Rwanda Saudi Arabia Solomon Islands Seychelles Sudan Sweden Singapore Saint Helena Slovenia Svalbard and Jan Mayen Slovakia Sierra Leone San Marino Senegal Somalia Suriname South Sudan Sao Tome and Principe El Salvador Sint Maarten Syria Swaziland Turks and Caicos Islands Chad French Southern Territories Togo Thailand Tajikistan Tokelau East Timor Turkmenistan Tunisia Tonga Turkey Trinidad and Tobago Tuvalu Taiwan Tanzania Ukraine Uganda United States Minor Outlying Islands United States Uruguay Uzbekistan Vatican Saint Vincent and the Grenadines Venezuela British Virgin Islands U.S. Virgin Islands Vietnam Vanuatu Wallis and Futuna Samoa Kosovo Yemen Mayotte South Africa Zambia Zimbabwe

Access to this information is restricted to persons who are located outside the United States, Canada, Japan and Australia.

This information is not intended for, and shall not be accessible, published, distributed or circulated to persons resident or located in the United States of America (the “United States”, which shall include its territories and possessions), Canada, Japan or Australia, and is not an offer to subscribe for or sell, nor a solicitation of an offer to subscribe for or buy shares of Nanobiotix in the United States, Canada, Japan or Australia. With respect to Member States of the European Economic Area that have transposed European Directive 2003/71/EC of the European Parliament and European Council (as amended in particular by Directive 2010/73/EU to the extent that the said Directive has been transposed into each Member State of the European Economic Area) (the “Prospectus Directive”), no action has been taken or will be taken topermit a public offering of the securities of Nanobiotix which would require the publication of a prospectus in any Member State. Shares in Nanobiotix may not be offered or sold in the United States unless registered with the Securities and Exchange Commission under the U.S. Securities Act of 1933, as amended, or unless an exemption from such registration applies. Nanobiotix does not intend to register securities or conduct a public offering in the United States, or in any other jurisdiction. Access to the information and documents contained in the following pages may be illegal in certain countries and only certain categories of persons may be authorized to access this information and these documents. Any person resident in a country other than France, the United States, Canada, Japan or Australia who wishes to access the information and documents contained on this website must first satisfy himself that he is not subject to local laws or regulations prohibiting or restricting such right of access or requiring registration or approval of the securities in order to acquire them. Nanobiotix will not accept any liability arising out of the breach by any person of the applicable laws or regulations. I therefore certify that: (1) I am not a resident of the United States, Canada, Australia or Japan nor am I currently physically present in any one of those countries; (2) I am authorized to access the information and documents presented on thiswebsite without being subject to any legal restriction and without any further actionbeing necessary on the part of Nanobiotix. I have read and understood the above declarations and certify below that they areaccurate, and hereby undertake to comply with all the conditions set forth on thispage.

Agree & download

Sorry

Access to this information is restricted to persons who are located outside the United States, Canada, Japan and Australia.

04/04/2019

Scientific Clinical | Nanobiotix announces first ever radioenhancer to receive european market approval

• Download en

04/02/2019

Scientific Clinical | Combination of first-in-class NBTXR3, radiotherapy, and anti-PD-1 immunotherapy demonstrate efficacy in treating resistant pre-clinical in vivo models of lung cancer

• Download en

03/26/2019

Scientific Clinical | Nanobiotix announces its clinical registration plan in Head and Neck cancers for the United States following FDA feedback

• Download en

03/15/2019

Financial | Nanobiotix 2018 Annual Results

• Download en

03/04/2019

Financial | Nanobiotix receives €14 million through the second tranche disbursement of financing from the European Investment Bank

• Download en

02/28/2019

Financial | Nanobiotix 2018 Q4 and annual revenues

• Download en

01/16/2019

Financial | Nanobiotix Plans to Conduct Registered Public Offering in the United States

• Download en

01/07/2019

Scientific Clinical | Nanobiotix and MD Anderson Cancer Center announce a large-scale, comprehensive clinical collaboration on NBTXR3

• Download en

11/15/2018

Financial | Nanobiotix revenues for the 3rd quarter of 2018

• Download en

10/19/2018

Scientific Clinical | NANOBIOTIX: Positive phase II/III results for NBTXR3 in Soft Tissue Sarcoma presented at ESMO

• Download en

10/16/2018

Corporate | Nanobiotix receives first tranche disbursement of 16 million euros financing from European Investment Bank

• Download en

09/26/2018

Scientific Clinical | Nanobiotix to present positive results from its phase II/III clinical trial of NBTXR3 in patients with STS and other ongoing phase I/II trials at ESMO and ASTRO

• Download en

09/20/2018

Scientific Clinical | Nanobiotix: Update on Head and Neck Phase I/II Trial with NBTXR3 and Other program data presented at ImmunoRad 2018

• Download en

09/04/2018

Financial | Nanobiotix half year results for the six months ended June 30, 2018

• Download en

07/26/2018

Financial | Nanobiotix signs a 40 M€ non-dilutive financing agreement with the European Investment Bank

• Download en

07/12/2018

Financial | NANOBIOTIX revenue for the 2nd quarter of 2018

• Download en

06/21/2018

Scientific Clinical | Nanobiotix announces positive phase II/III topline data in soft tissue sarcoma with NBTXR3

• Download en

06/06/2018

Financial | NANOBIOTIX’ Management statement on recent share price variation

• Download en

05/15/2018

Financial | NANOBIOTIX revenue for the 1st quarter of 2018

• Download en

05/03/2018

Scientific Clinical | Nanobiotix partners with Weill Cornell Medicine on pre-clinical studies to evaluate the impact of NBTXR3 on cGAS-STING pathway in mammary cancers

• Download en

04/26/2018

Financial | NANOBIOTIX selected to enter Euronext’s Tech 40 Label

• Download en

04/17/2018

Scientific Clinical | AACR annual meeting 2018: Nanobiotix presented preclinical data showing NBTXR3 nanoparticles can activate the cGAS-STING pathway

• Download en

04/10/2018

Scientific Clinical | The University of Texas MD Anderson Cancer Center and Nanobiotix have an agreement to run immunotherapeutic pre-clinical research in lung cancer combining NBTXR3 & Nivolumab

• Download en

03/30/2018

Financial | Nanobiotix 2017 Annual Results

• Download en

02/28/2018

Financial | Nanobiotix 2017 Q4 and annual revenues

• Download en

01/22/2018

Scientific Clinical | Nanobiotix presents first promising data from Phase I/II Liver Cancers trial of NBTXR3 at American Society Of Clinical Oncology Gastroin­testinal Annual Meeting

• Download en

01/11/2018

Scientific Clinical | Nanobiotix partners with the Providence Cancer Institute to run immunotherapeutic preclinical research in pancreatic cancers

• Download en

08/08/2019

Nanobiotix launches a private placement

• Download en

12/26/2017

Corporate | Nanobiotix: 2017 review and 2018 expected milestones

• Download en

12/26/2017

Scientific Clinical | FDA approves Nanobiotix’s first Immuno-Oncology trial

• Download en

11/15/2017

Financial | Nanobiotix revenues for the 3rd quarter of 2017

• Download en

11/13/2017

Scientific Clinical | Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3’s significant potential role in Immuno-Oncology at SITC Annual Meeting

• Download en

11/09/2017

Scientific Clinical | Nanobiotix provides update on the global development of its lead product NBTXR3

• Download en

10/31/2017

Financial | Nanobiotix successfully completes approximately eur 27.2 million placement of new shares

• Download en

10/30/2017

Financial | Nanobiotix launches capital increase by means of an accelerated bookbuild offering

• Download en

Nanobiotix launches capital increase by means of an accelerated bookbuild offering

The following pages contain information regarding the placement of Nanobiotix. For regulatory reasons, the distribution of the content of such information is restricted. Consequently, please fill out the fields below to access such information.

Your country: Select your country Andorra United Arab Emirates Afghanistan Antigua and Barbuda Anguilla Albania Armenia Angola Antarctica Argentina American Samoa Austria Australia Aruba Aland Islands Azerbaijan Bosnia and Herzegovina Barbados Bangladesh Belgium Burkina Faso Bulgaria Bahrain Burundi Benin Saint Barthelemy Bermuda Brunei Bolivia Bonaire, Saint Eustatius and Saba Brazil Bahamas Bhutan Bouvet Island Botswana Belarus Belize Canada Cocos Islands Democratic Republic of the Congo Central African Republic Republic of the Congo Switzerland Ivory Coast Cook Islands Chile Cameroon China Colombia Costa Rica Cuba Cape Verde Curacao Christmas Island Cyprus Czech Republic Germany Djibouti Denmark Dominica Dominican Republic Algeria Ecuador Estonia Egypt Western Sahara Eritrea Spain Ethiopia Finland Fiji Falkland Islands Micronesia Faroe Islands France Gabon United Kingdom Grenada Georgia French Guiana Guernsey Ghana Gibraltar Greenland Gambia Guinea Guadeloupe Equatorial Guinea Greece South Georgia and the South Sandwich Islands Guatemala Guam Guinea-Bissau Guyana Hong Kong Heard Island and McDonald Islands Honduras Croatia Haiti Hungary Indonesia Ireland Israel Isle of Man India British Indian Ocean Territory Iraq Iran Iceland Italy Jersey Jamaica Jordan Japan Kenya Kyrgyzstan Cambodia Kiribati Comoros Saint Kitts and Nevis North Korea South Korea Kuwait Cayman Islands Kazakhstan Laos Lebanon Saint Lucia Liechtenstein Sri Lanka Liberia Lesotho Lithuania Luxembourg Latvia Libya Morocco Monaco Moldova Montenegro Saint Martin Madagascar Marshall Islands Macedonia Mali Myanmar Mongolia Macao Northern Mariana Islands Martinique Mauritania Montserrat Malta Mauritius Maldives Malawi Mexico Malaysia Mozambique Namibia New Caledonia Niger Norfolk Island Nigeria Nicaragua Netherlands Norway Nepal Nauru Niue New Zealand Oman Panama Peru French Polynesia Papua New Guinea Philippines Pakistan Poland Saint Pierre and Miquelon Pitcairn Puerto Rico Palestinian Territory Portugal Palau Paraguay Qatar Reunion Romania Serbia Russia Rwanda Saudi Arabia Solomon Islands Seychelles Sudan Sweden Singapore Saint Helena Slovenia Svalbard and Jan Mayen Slovakia Sierra Leone San Marino Senegal Somalia Suriname South Sudan Sao Tome and Principe El Salvador Sint Maarten Syria Swaziland Turks and Caicos Islands Chad French Southern Territories Togo Thailand Tajikistan Tokelau East Timor Turkmenistan Tunisia Tonga Turkey Trinidad and Tobago Tuvalu Taiwan Tanzania Ukraine Uganda United States Minor Outlying Islands United States Uruguay Uzbekistan Vatican Saint Vincent and the Grenadines Venezuela British Virgin Islands U.S. Virgin Islands Vietnam Vanuatu Wallis and Futuna Samoa Kosovo Yemen Mayotte South Africa Zambia Zimbabwe

Access to this information is restricted to persons who are located outside the United States, Canada, Japan and Australia.

This information is not intended for, and shall not be accessible, published, distributed or circulated to persons resident or located in the United States of America (the “United States”, which shall include its territories and possessions), Canada, Japan or Australia, and is not an offer to subscribe for or sell, nor a solicitation of an offer to subscribe for or buy shares of Nanobiotix in the United States, Canada, Japan or Australia. With respect to Member States of the European Economic Area that have transposed European Directive 2003/71/EC of the European Parliament and European Council (as amended in particular by Directive 2010/73/EU to the extent that the said Directive has been transposed into each Member State of the European Economic Area) (the “Prospectus Directive”), no action has been taken or will be taken topermit a public offering of the securities of Nanobiotix which would require the publication of a prospectus in any Member State. Shares in Nanobiotix may not be offered or sold in the United States unless registered with the Securities and Exchange Commission under the U.S. Securities Act of 1933, as amended, or unless an exemption from such registration applies. Nanobiotix does not intend to register securities or conduct a public offering in the United States, or in any other jurisdiction. Access to the information and documents contained in the following pages may be illegal in certain countries and only certain categories of persons may be authorized to access this information and these documents. Any person resident in a country other than France, the United States, Canada, Japan or Australia who wishes to access the information and documents contained on this website must first satisfy himself that he is not subject to local laws or regulations prohibiting or restricting such right of access or requiring registration or approval of the securities in order to acquire them. Nanobiotix will not accept any liability arising out of the breach by any person of the applicable laws or regulations. I therefore certify that: (1) I am not a resident of the United States, Canada, Australia or Japan nor am I currently physically present in any one of those countries; (2) I am authorized to access the information and documents presented on thiswebsite without being subject to any legal restriction and without any further actionbeing necessary on the part of Nanobiotix. I have read and understood the above declarations and certify below that they areaccurate, and hereby undertake to comply with all the conditions set forth on thispage.

Agree & download

Sorry

Access to this information is restricted to persons who are located outside the United States, Canada, Japan and Australia.

10/23/2017

Scientific Clinical | Nanobiotix completes patient inclusion for Phase II/III trial of NBTXR3 in soft tissue sarcoma

• Download en

09/28/2017

Scientific Clinical | Nanobiotix plans to conduct its first clinical trial with NBTXR3 in combination with immune checkpoint inhibitors in the U.S.

• Download en

08/31/2017

Financial | Nanobiotix half year results for the six months ended 30 June 2017

• Download en

07/12/2017

Financial | Nanobiotix revenues for the 2nd quarter of 2017

• Download en

06/15/2017

Scientific Clinical | NANOBIOTIX: new translational data presented at ASTRO, NCI AND SITC’S Immunotherapy Workshop

• Download en

06/05/2017

Scientific Clinical | NANOBIOTIX: promising data from phase I/II Head and Neck cancer trial with NBTXR3 presented at the American Society of Clinical Oncology’s Annual Meeting

• Download en

05/18/2017

Scientific Clinical | NANOBIOTIX announces first positive Human data showing that NBTXR3 could become a backbone in Immuno-Oncology

• Download en

05/15/2017

Financial | Nanobiotix revenue for the 1st quarter of 2017

• Download en

04/28/2017

Financial | Nanobiotix: 2016 Annual Results

• Download en

04/07/2017

Financial | Nanobiotix successfully completes approx. EUR 25.1 million private placement of new shares

• Download en

04/04/2017

Corporate | Nanobiotix expands its clinical development in Head and Neck cancer and Immuno-Oncology ; new clinical data to be presented at ASCO

• Download en

03/23/2017

Scientific Clinical | NANOBIOTIX: the Independent Data Monitoring Committee recommends the continuation of the ongoing phase II/III trial of NBTXR3 in Soft Tissue Sarcoma

• Download en

03/07/2017

Scientific Clinical | Nanobiotix to present preclinical data on nanoparticle radioenhancer NBTXR3 at the AACR Annual Meeting 2017

• Download en

02/28/2017

Financial | Nanobiotix 2016 Q4 and annual revenues

• Download en

02/07/2017

Corporate | Nanobiotix appoints senior executive from pharmaceutical industry, as Chief Operating Officer

• Download en

01/31/2017

Corporate | Nanobiotix: 2016 review and 2017 anticipated milestones

• Download en

12/13/2019

Scientific Clinical | FDA approved Investigational New Drug for NBTXR3 in a new clinical study in prostate cancer

• Download en

12/14/2016

Scientific Clinical | Nanobiotix reports positive Phase I/II preliminary data on feasibility and safety of NBTXR3 in liver cancers trial

• Download en

11/28/2016

Scientific Clinical | Nanobiotix Provides Update on Global Development of Lead Product NBTXR3

• Download en

11/15/2016

Financial | Nanobiotix revenue for Q3 2016

• Download en

11/14/2016

Scientific Clinical | Nanobiotix presents NBTXR3 preclinical data demonstrating its potential usage as in situ vaccine for cancer

• Download en

10/20/2016

Scientific Clinical | Nanobiotix’s partner, PharmaEngine, has launched a new NBTXR3 clinical trial in head and neck cancers in Asia

• Download en

10/03/2016

Corporate | Nanobiotix Strengthens U.S. leadership with appointments of Head of U.S. Clinical Development and Director of Investor Relations

• Download en

09/19/2016

Financial | Bpifrance grants Nanobiotix a 2M€ interest-free loan to support final development stage of lead product, NBTXR3

• Download en

09/13/2016

Corporate | Nanobiotix announces submission for first market approval of lead product NBTXR3 in Europe

• Download en

08/31/2016

Financial | Nanobiotix half year results for the six months ended 30 June 2016

• Download en

07/13/2016

Financial | Nanobiotix revenue for Q2 2016

• Download en

07/06/2016

Scientific Clinical | Nanobiotix reports successful results from Phase I/II Trial of NBTXR3 in Head & Neck Cancer

• Download en

06/14/2016

Financial | Nanobiotix announces exercise of warrants by Capital Venture International

• Download en

05/31/2016

Corporate | Nanobiotix receives US$1m milestone payment from PharmaEngine

• Download en

05/31/2016

Scientific Clinical | Nanobiotix establishes promising preclinical proof-of-concept in Immuno Oncology

• Download en

05/13/2016

Financial | Revenue for the 1st quarter of 2016

• Download en

04/29/2016

Financial | Nanobiotix 2015 Annual Results

• Download en

03/11/2016

Financial | Nanobiotix completes a EUR 21 million private placement

• Download en

11/13/2015

Financial | Nanobiotix Revenue Q3 2015

• Download en

11/13/2015

Scientific Clinical | Nanobiotix’s Soft Tissue Sarcoma pivotal trial progressing well as planned: already 7 countries and 29 sites opened

• Download en

08/27/2015

Financial | Nanobiotix Half Year Results for the period ended 30 June 2015

• Download en

07/15/2015

Financial | Nanobiotix Revenue Q2 2015

• Download en

07/01/2015

Scientific Clinical | Nanobiotix starts Phase I/II clinical trial in liver Metastasis and Hepatocellular Cancer with its lead product NBTXR3

• Download en

06/09/2015

Scientific Clinical | Nanobiotix reports positive preliminary results in Head and Neck cancer Phase I/II clinical trial with NBTXR3

• Download en

05/13/2015

Financial | Nanobiotix Revenue Q1 2015

• Download en

05/11/2015

Scientific Clinical | Nanobiotix expands Soft Tissue Sarcoma pivotal clinical trial across Europe and beyond, according to plan

• Download en

04/14/2015

Financial | Nanobiotix 2014 Annual Results

• Download en

03/18/2015

Corporate | Nanobiotix appoints its Manufacturing Partner, CordenPharma : another step towards commercialization

• Download en

02/27/2015

Financial | Nanobiotix 2014 Q4 and annual revenues

• Download en

02/19/2015

Corporate | Professor Robert Langer joins Nanobiotix as Scientific Advisor

• Download en

11/25/2014

Financial | Nanobiotix secures financing from a major US investor, to address the US market

• Download en

11/14/2014

Financial | Nanobiotix 2014 Q3 Revenues

• Download en

10/16/2014

Scientific Clinical | Nanobiotix receives first approval to start phase II/III registration trial in soft tissue sarcoma in Europe

• Download en

10/13/2014

Financial | Nanobiotix reaches the second milestone payment of Bpifrance dedicated to NBTXR3 development in liver cancers

• Download en

10/08/2014

Scientific Clinical | PharmaEngine will join Nanobiotix’ pivotal trial for NBTXR3 in Soft Tissue Sarcoma to accelerate its development in Asia-Pacific

• Download en

09/22/2014

Corporate | Nanobiotix expands operations into the USA

• Download en

08/28/2014

Financial | Nanobiotix Half year Results for the period ended 30 june 2014

• Download en

07/11/2014

Financial | Nanobiotix 2014 Q2 Revenues

• Download en

06/17/2014

Financial | Nanobiotix joins the CAC® PME Index

• Download en

06/02/2014

Scientific Clinical | Nanobiotix presents successful Phase I results for its lead nanomedicine product NBTXR3 at ASCO

• Download en

05/12/2014

Financial | Nanobiotix Revenue Q1 2014 and new composition shareholding

• Download en

04/15/2014

Corporate | Nanobiotix appoints Thierry Otin as Head of Manufacturing and supply

• Download en

04/11/2014

Financial | Nanobiotix 2013 Annual Results

• Download en

04/01/2014

Scientific Clinical | Nanobiotix selected to present data from NBTXR3 clinical trial at ASCO

• Download en

02/10/2014

Scientific Clinical | Nanobiotix sees Clinical Advance in Soft Tissue Sarcoma Pilot Trial with Lead Product, NBTXR3

• Download en

01/31/2014

Financial | Nanobiotix 2013 annual revenues

• Download en

01/16/2014

Corporate | Nanobiotix strengthens its Supervisory Board

• Download en

01/07/2014

Corporate | Nanobiotix 2014 Review, 2015 Anticipated Milestones and Financial Calendar

• Download en

12/10/2013

Corporate | Nanomedicine Map reveals the European landscape and potential

• Download en

12/06/2013

Scientific Clinical | Nanobiotix strengthens its NanoXray pipeline with the launch of NBTX-TOPO development, the first nanotherapeutic with embedded radar

• Download en

11/12/2013

Financial | Nanobiotix Q3 Revenue 2013

• Download en

11/07/2013

Corporate | Nanobiotix honored at the INVESTOR AWARDS 2013 in the “Young Talent” category

• Download en

09/23/2013

Corporate | Nanobiotix strengthens its management team

• Download en

08/30/2013

Financial | Nanobiotix Half Year Results for the period ended 30 June 2013

• Download en

07/12/2013

Financial | Nanobiotix 2013 Q2 revenue

• Download en

07/03/2013

Corporate | Nanobiotix announces €2.8 million grant from bpifrance to accelerate development of NBTXR3 in a third new indication

• Download en

06/26/2013

Scientific Clinical | Nanobiotix announces the selection of its second NanoXray product, NBTX-IV and a collaboration with the NCI for development

• Download en

06/13/2013

Scientific Clinical | Nanobiotix receives approval from ANSM to start new Clinical Trial with Lead Product NBTXR3

• Download en

06/03/2013

Scientific Clinical | Nanobiotix’s NBTXR3 Achieves Clinical Milestone Reaching Proof-Of- Concept in Phase I Trial of Soft Tissue Sarcoma

• Download en

05/15/2013

Financial | Nanobiotix 2013 Q1 revenues

• Download en

04/25/2013

Financial | Nanobiotix 2012 Annual Results

• Download en

04/03/2013

Corporate | Dr. Laurent Levy, CEO of Nanobiotix, receives the UB Entrepreneurship Award from the University at Buffalo, SUNY

• Download en

03/19/2013

Corporate | Nanobiotix Selected to Present at Future Leaders in the Biotech Industry Conference

• Download en

02/13/2013

Corporate | Nanobiotix appoints Dr Alain Herrera to the Supervisory Board

• Download en

01/25/2013

Financial | Nanobiotix 2012 revenues

• Download en

01/14/2013

Financial | 2013 Financial agenda

• Download en

01/07/2013

Corporate | Nanobiotix 2013 Review Significant Corporate and Clinical Progress

• Download en

12/05/2012

Corporate | Laurent Levy, CEO Nanobiotix, elected Vice-Chairman of the ETPN

• Download en

11/13/2012

Scientific Clinical | Phase I Independent Data Monitoring Committee confirms good safety of NBTXR3 in the first group of patients with advanced STS

• Download en

10/03/2012

Corporate | Nanomed2020 intends to bring more nanomedicine products to European patients

• Download en

08/05/2012

Corporate | PharmaEngine and Nanobiotix Sign Asia-Pacific Exclusive License and Collaboration Agreement for NBTXR3

• Download en

05/02/2012

Scientific Clinical | Nanobiotix and Thomas Jefferson University Start Research Collaboration

• Download en

04/24/2012

Corporate | Nanobiotix appoints Dr. Bernd Muehlenweg as a member of the Executive Board

• Download en

11/24/2011

Financial | Nanobiotix receives 1 million euro from OSEO

• Download en

09/13/2011

Scientific Clinical | Nanobiotix Starts Clinical Trial with Lead Product NBTXR3

• Download en

04/04/2011

Corporate | Nanobiotix announces changes to the non-executive board

• Download en

02/02/2011

Corporate | Nanbiotix welcomes Dr Bernd Mühlenweg as Head of Business Development

• Download en

09/07/2010

Corporate | Nanobiotix welcomes Laurent Condomine on board

• Download en